Bactrim: Potent Dual-Antibiotic Therapy for Bacterial Infections
| Product dosage: 480mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.46 | $41.17 (0%) | 🛒 Add to cart |
| 120 | $0.42 | $54.89 $50.20 (9%) | 🛒 Add to cart |
| 180 | $0.38 | $82.33 $68.27 (17%) | 🛒 Add to cart |
| 270 | $0.36 | $123.50 $97.39 (21%) | 🛒 Add to cart |
| 360 | $0.34
Best per pill | $164.66 $121.49 (26%) | 🛒 Add to cart |
Bactrim is a combination antibiotic medication containing sulfamethoxazole and trimethoprim, designed to target and eliminate a broad spectrum of susceptible bacterial strains. It operates through a synergistic mechanism that inhibits sequential steps in bacterial folate synthesis, effectively disrupting DNA production and halting bacterial proliferation. This formulation is widely prescribed for both common and serious infections, offering reliable efficacy when used under appropriate medical guidance. Healthcare providers value its established history in treating urinary tract infections, respiratory conditions, and certain opportunistic infections.
Features
- Contains sulfamethoxazole 400 mg and trimethoprim 80 mg per tablet
- Dual-mechanism action inhibits bacterial dihydrofolate reductase and dihydropteroate synthase
- Available in oral tablet and liquid suspension formulations
- Broad-spectrum coverage against Gram-positive and Gram-negative bacteria
- Bioavailability of approximately 90% when taken orally
- Peak plasma concentrations reached within 1-4 hours post-administration
- Half-life of 8-10 hours in patients with normal renal function
- FDA-approved for multiple indications including UTI, acute otitis media, and traveler’s diarrhea
Benefits
- Effectively treats resistant bacterial strains through synergistic antibiotic action
- Comprehensive coverage reduces the need for multiple antibiotic regimens
- Rapid onset of action provides prompt symptomatic relief
- Well-established safety profile with decades of clinical use
- Convenient twice-daily dosing supports treatment adherence
- Cost-effective alternative to newer broad-spectrum antibiotics
Common use
Bactrim is primarily indicated for the treatment of urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris. It is also commonly prescribed for acute exacerbations of chronic bronchitis in adults when caused by susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. In pediatric patients, Bactrim is used for acute otitis media caused by susceptible strains of H. influenzae or S. pneumoniae when in the judgment of the physician it offers an advantage over other antimicrobials. The medication finds additional application in the treatment of traveler’s diarrhea caused by enterotoxigenic E. coli, and for Pneumocystis jirovecii pneumonia prophylaxis and treatment in immunocompromised patients, particularly those with HIV/AIDS.
Dosage and direction
For urinary tract infections and shigellosis in adults and children over 2 months: The usual adult dosage is 1 double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) every 12 hours for 10-14 days. For children, the recommended dose is 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours, administered in two divided doses every 12 hours for 10 days.
For acute otitis media in children: 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours, given in two divided doses every 12 hours for 10 days.
For chronic bronchitis exacerbations in adults: 1 double-strength tablet every 12 hours for 14 days.
For Pneumocystis jirovecii pneumonia treatment: 15-20 mg/kg trimethoprim and 75-100 mg/kg sulfamethoxazole per 24 hours given in equally divided doses every 6-8 hours for 14-21 days.
For Pneumocystis jirovecii pneumonia prophylaxis: 1 double-strength tablet daily or three times per week.
The medication should be taken with a full glass of water, and patients should maintain adequate fluid intake to prevent crystalluria and stone formation. Administration with food may minimize gastrointestinal upset.
Precautions
Patients should be advised to complete the full course of therapy even if symptoms improve before the medication is finished. Regular monitoring of complete blood counts is recommended during prolonged therapy due to potential hematologic effects. Renal function should be assessed before and during treatment, with dosage adjustments necessary for patients with impaired renal function (creatinine clearance below 30 mL/min). Hepatic function should be monitored in patients with pre-existing liver disease. Bactrim may cause photosensitivity reactions; patients should be advised to use sunscreen and protective clothing when exposed to sunlight. Caution is advised in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Elderly patients may be more susceptible to adverse reactions, particularly severe skin reactions and bone marrow suppression. Regular potassium monitoring is recommended, especially in patients with underlying potassium abnormalities, those taking angiotensin-converting enzyme inhibitors, or elderly patients.
Contraindications
Bactrim is contraindicated in patients with documented hypersensitivity to trimethoprim, sulfonamides, or any component of the formulation. It should not be used in patients with megaloblastic anemia due to folate deficiency. Contraindicated in pregnancy at term and during the nursing period because sulfonamides may cause kernicterus in newborns. Should not be used in infants less than 2 months of age. Contraindicated in patients with marked hepatic damage or severe renal insufficiency when repeated serum level measurements cannot be performed. Avoid use in patients with history of drug-induced immune thrombocytopenia with trimethoprim or sulfonamides.
Possible side effect
Common adverse reactions include nausea (3.7%), vomiting (1.1%), diarrhea (1.1%), and loss of appetite (0.7%). Dermatological reactions may occur, including rash (2.9%), urticaria, and photosensitivity. Hematologic effects may include thrombocytopenia (0.4%), leukopenia (0.5%), neutropenia (0.4%), and megaloblastic anemia. Elevated liver enzymes occur in approximately 2.5% of patients. Hyperkalemia has been reported, particularly at high doses. Rare but serious reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, hepatic necrosis, and interstitial nephritis. Psychiatric side effects may include depression, hallucinations, and apathy. Neurological effects can include headache, dizziness, and peripheral neuropathy with prolonged use.
Drug interaction
Bactrim may potentiate the effects of warfarin, requiring close monitoring of prothrombin time. It may enhance the hypoglycemic effects of sulfonylurea drugs. Concurrent use with angiotensin-converting enzyme inhibitors or potassium-sparing diuretics may increase the risk of hyperkalemia. Bactrim may increase concentrations of phenytoin, necessitating monitoring of phenytoin levels. Methotrexate levels may be increased, increasing toxicity risk. Cyclosporine levels may be elevated, increasing nephrotoxicity risk. Thiazide diuretics may increase the risk of thrombocytopenia in elderly patients. Bactrim may decrease the efficacy of oral contraceptives; alternative contraceptive methods should be considered. Concomitant use with drugs that cause bone marrow depression may increase hematologic toxicity.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed dose. Maintaining consistent blood levels is important for effectiveness, so patients should try to adhere to the prescribed schedule. Setting reminders or using pill organizers can help maintain consistent dosing. If multiple doses are missed, patients should contact their healthcare provider for guidance.
Overdose
Symptoms of overdose may include nausea, vomiting, dizziness, headache, mental depression, confusion, and bone marrow depression. Massive overdose may result in jaundice, crystalluria, hematuria, and oliguria. Serum levels exceeding 100 μg/mL of sulfamethoxazole or 10 μg/mL of trimethoprim may indicate overdose. Treatment is supportive and symptomatic. Gastric lavage may be performed if ingestion was recent. Maintain adequate fluid intake and urinary output to prevent crystalluria. Acidification of urine may increase renal elimination of trimethoprim but may increase the risk of sulfonamide crystallization. Hemodialysis may be moderately effective in removing both components, particularly trimethoprim. Blood counts should be monitored for potential hematologic toxicity.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). Keep container tightly closed and protect from light and moisture. Keep out of reach of children and pets. Do not store in bathroom cabinets where moisture levels may fluctuate. The oral suspension should be shaken well before each use and discarded after the expiration date or if contamination is suspected. Do not freeze the liquid formulation. Tablets should be kept in their original packaging until use to protect from light degradation.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Bactrim is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The information provided here is not exhaustive and does not cover all possible uses, directions, precautions, or adverse effects. Patients should consult with their healthcare provider for complete information about their specific medical condition and treatment options. Never disregard professional medical advice or delay seeking it because of something you have read in this product information. Healthcare providers should reference the complete prescribing information before administering this medication.
Reviews
Clinical studies demonstrate Bactrim’s efficacy with clinical success rates of 85-95% for uncomplicated urinary tract infections. Meta-analyses show equivalent effectiveness to fluoroquinolones for certain indications with potentially lower resistance development. Many clinicians report satisfactory results in community-acquired infections, particularly noting its value in areas with known resistance patterns. Some reviews highlight concerns about increasing resistance rates among urinary pathogens, necessitating culture confirmation before use in complicated infections. Patients generally report good tolerance, though gastrointestinal side effects are commonly noted. The fixed combination is praised for convenience but criticized by some infectious disease specialists for limiting dosing flexibility in special populations. Long-term use for prophylaxis receives positive assessment for preventing Pneumocystis pneumonia in immunocompromised patients.